# A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

> **NCT07318805** · PHASE1 · RECRUITING · sponsor: **Pfizer** · enrollment: 260 (estimated)

## Conditions studied

- Advanced Breast Cancer
- Metastatic Breast Cancer (HR+/ HER2-)
- Colorectal Cancer
- Metastatic Colorectal Adenocarcinoma
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** PF-08032562
- **DRUG:** Fulvestrant
- **DRUG:** Cetuximab
- **DRUG:** Fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07318805
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-23
- **Primary completion:** 2029-04-14
- **Final completion:** 2030-04-14
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07318805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07318805, "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT07318805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*